Compare Comfort Systems USA Inc (FIX) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Comfort Systems USA Inc vs Viatris Inc — how do they compare? Comfort Systems USA Inc trades at $1,661.86 (market cap $61.14B), while Viatris Inc trades at $17.25 (market cap $19.44B). The key difference: Comfort Systems USA Inc is far larger — about 3.1× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.88%). Which is the better fit depends on your goals.
| FIX | VTRS | |
|---|---|---|
Market Cap | $61.14B | $19.44B |
Sector | Technology | Health |
52-Week High | $2.07K | $17.39 |
52-Week Low | $532.14 | $8.74 |
Enterprise Value | $60.42B | $31.65B |
Dividend Yield | 0.15% | 2.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Comfort Systems USA (FIX) trades at $1,694.14, down 4.56% amid bearish technical signals, though fundamentals remain strong with Q1 2026 EPS beating estimates at $10.51 versus $6.81 expected. Revenue growth is robust, projected to rise from $9.10B in 2025 to $10.1B in 2026, while net profit margins improve to 12.07%. The company benefits from AI infrastructure demand and a record backlog, though valuation multiples appear elevated with a P/E of 50.14.
Outlook is mixed: analyst consensus is bullish with a $2,100 price target and 55.56% buy ratings, but technical indicators signal near-term pressure. Key risks include execution challenges from rapid growth and premium valuation. The stock offers growth exposure to data center and construction markets, but investors should weigh high multiples against earnings momentum.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Comfort Systems USA Inc
Comfort Systems USA is a premier provider of mechanical and electrical contracting services. It specializes in HVAC, plumbing, and energy management solutions for commercial and industrial facilities.
Read more on FIX →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
